Preliminary Results, Conferences, Stock Price Movements, and Acquisitions - Research Report on Community Health, ArthroCare,

 Preliminary Results, Conferences, Stock Price Movements, and Acquisitions -
Research Report on Community Health, ArthroCare, NuPathe, Zalicus, and Neogen

PR Newswire

NEW YORK, January 13, 2014

NEW YORK, January 13, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Community
Health Systems, Inc. (NYSE: CYH), ArthroCare Corporation (NASDAQ: ARTC),
NuPathe, Inc. (NASDAQ: PATH), Zalicus Inc. (NASDAQ: ZLCS), and Neogen Corp.
(NASDAQ: NEOG). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Community Health Systems, Inc. Research Report

On January 6, 2014, Community Health Systems Inc. (Community Health) announced
its preliminary financial and operating results for full-year 2013 as well as
its preliminary guidance for 2014. The Company stated that for 2013, it
expects net operating revenues to range from $12.98 billion to $13.00 billion
and adjusted EBITDA to range from $1.83 billion to $1.85 billion. Further, the
Company also provided guidance for 2014, reflecting the acquisition of HMA as
if it took place on January 1, 2014. The Company stated that it anticipates
net operating revenues less provision for bad debts to range from $19.7
billion to $21.2 billion, and adjusted EBITDA for 2014 is expected to be from
$2.9 billion to $3.2 billion. The Company added that it anticipates reporting
its complete 2013 financial results on February 18, 2014, along with an
earnings call on February 19, 2014. The Full Research Report on Community
Health Systems, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/7587_CYH

--

ArthroCare Corporation Research Report

On January 6, 2014, ArthroCare Corp. (ArthroCare) announced that it will
present at the upcoming 32^nd Annual J.P. Morgan Healthcare Conference on
January 14, 2014 at 3:30 p.m. PT in San Francisco, California. ArthroCare
informed that David Fitzgerald, President and CEO, will deliver the business
presentation at the conference. The Company added that the presentation will
be webcast live and can be accessed at its website, where it will be archived
for 30 days after the presentation. The Full Research Report on ArthroCare
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/bc51_ARTC

--

NuPathe, Inc. Research Report

On January 8, 2014, NuPathe Inc.'s (NuPathe) stock went up to end the day at
$4.38 compared to the previous day's closing price of $3.23, representing a
35.60% rise. The Company's stock increased 35.19% during the past three
trading days, compared to the Dow Jones Industrial Average which decreased
0.04% over the same trading period. The Full Research Report on NuPathe, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d5b0_PATH

--

Zalicus Inc. Research Report

On January 8, 2014, Zalicus Inc.'s (Zalicus) stock went up to end the day at
$1.78 compared to the previous day's closing price of $1.32, resulting in a
34.85% rise. The Company's stock increased 45.90% during the past three
trading days, compared to the Dow Jones Industrial Average which decreased
0.04% over the same trading period. The Full Research Report on Zalicus Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/cbb5_ZLCS

--

Neogen Corp. Research Report

On January 2, 2014, Neogen Corp. (Neogen) announced its acquisition of
Chem-Tech Ltd (Chem-Tech), an insecticides manufacturer for animal and food
industries. James Herbert, Neogen CEO and Chairman, commented, "The Chem-Tech
business will significantly add to Neogen's position of being the 'one-stop
shop' for meat, milk and egg producers. Chem-Tech's Turbocide® products are
also becoming popular for the fogging of food storage and warehouses." Dr.
Jason Lilly, Neogen's Vice President of corporate development, added,
"Chem-Tech fits the Neogen model of supplementing our organic growth with
growth through acquisitions. Like many of our acquisitions, we will be able to
consolidate administrative, sales, and research and development with our
existing groups. We expect to continue to operate the company's manufacturing
facility in Iowa along with significant portions of its warehousing and
distribution." According to the Company, most of Chem-Tech's customers and
distributors are already Neogen's customers, with long-term relationships with
both the Companies. Neogen added that the purchase price for the acquisition
includes contingent payment consideration. The Full Research Report on Neogen
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/b1b4_NEOG

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.

1.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
2.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
3.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.